BIOVIE INC (BIVI) Stock Price, Forecast & Analysis
NASDAQ:BIVI • US09074F5044
BIVI Key Statistics, Chart & Performance
The current stock price of BIVI is 1.26 USD. In the past month the price increased by 3.28%. In the past year, price decreased by -91.49%.
BIVI Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to BIVI. When comparing the yearly performance of all stocks, BIVI is a bad performer in the overall market: 94.25% of all stocks are doing better.
BIVI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BIVI. While BIVI has a great health rating, there are worries on its profitability.
BIVI Financial Highlights
Over the last trailing twelve months BIVI reported a non-GAAP Earnings per Share(EPS) of -8.92. The EPS increased by 84.36% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -69.22% | ||
| ROE | -74.5% | ||
| Debt/Equity | 0 |
BIVI Forecast & Estimates
7 analysts have analysed BIVI and the average price target is 12.24 USD. This implies a price increase of 871.43% is expected in the next year compared to the current price of 1.26.
BIVI Ownership
BIVI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.75 | 404.235B | ||
| AMGN | AMGEN INC | 16.85 | 204.477B | ||
| GILD | GILEAD SCIENCES INC | 17.12 | 189.501B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.07 | 119.327B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.05 | 83.747B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.66 | 43.95B | ||
| INSM | INSMED INC | N/A | 32.227B | ||
| NTRA | NATERA INC | N/A | 29.989B | ||
| BIIB | BIOGEN INC | 12.76 | 28.491B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.15 | 20.499B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BIVI
Company Profile
BioVie, Inc. is a biopharmaceutical company, which engages in discovery, development, and marketing drug therapies for neurological and neurodegenerative disorders, and liver disease. The company is headquartered in Carson City, Nevada and currently employs 13 full-time employees. The company went IPO on 2014-01-14. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-kB, and the associated neuroinflammation and insulin resistance, but not ERK and NFkB homeostatic functions (such as insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of Alzheimer’s disease (AD) and Parkinson’s disease (PD). Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of long COVID. In liver disease, the Company's orphan drug candidate BIV201, is being evaluated for Phase III clinical testing for the reduction of further decompensation in participants with liver cirrhosis and ascites.
Company Info
BIOVIE INC
680 W Nye Lane, Suite 201
Carson City NEVADA 90404 US
CEO: Cuong Do
Employees: 13
Phone: 17758883162
BIOVIE INC / BIVI FAQ
What does BIVI do?
BioVie, Inc. is a biopharmaceutical company, which engages in discovery, development, and marketing drug therapies for neurological and neurodegenerative disorders, and liver disease. The company is headquartered in Carson City, Nevada and currently employs 13 full-time employees. The company went IPO on 2014-01-14. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-kB, and the associated neuroinflammation and insulin resistance, but not ERK and NFkB homeostatic functions (such as insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of Alzheimer’s disease (AD) and Parkinson’s disease (PD). Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of long COVID. In liver disease, the Company's orphan drug candidate BIV201, is being evaluated for Phase III clinical testing for the reduction of further decompensation in participants with liver cirrhosis and ascites.
Can you provide the latest stock price for BIOVIE INC?
The current stock price of BIVI is 1.26 USD. The price decreased by -1.56% in the last trading session.
Does BIOVIE INC pay dividends?
BIVI does not pay a dividend.
How is the ChartMill rating for BIOVIE INC?
BIVI has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists BIVI stock?
BIVI stock is listed on the Nasdaq exchange.
What sector and industry does BIOVIE INC belong to?
BIOVIE INC (BIVI) operates in the Health Care sector and the Biotechnology industry.
Is BIOVIE INC (BIVI) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BIVI.